Joseph Martinelli, MD
Pulmonary Disease · Duluth, MNNPI 1003867573
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.0%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 93.4% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $6,919, more than ten times the $119 reported in 2021. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $189.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Pulmonx Corporation$147
- Insmed, Inc.$130
- Inspire Medical Systems, Inc.$101
- GSK$25
- Boehringer Ingelheim$25
- plus $44 from 3 others
What the payments were for
- Travel & lodging$4,09957%
- Food & beverage$4616%
- Education$2,63037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $6,718 |
| Pulmonx Corporation | 2 | $147 |
| Insmed, Inc. | 8 | $130 |
| Inspire Medical Systems, Inc. | 5 | $101 |
| GSK | 2 | $25 |
| Boehringer Ingelheim | 2 | $25 |
| Amgen | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,633
How this compares
$7,190 in reported general payments places this provider in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 52 | $664,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 538 | $441,457 |
| Dupixent SyringeDupilumab | 68 | $265,105 |
| Orenitram ErTreprostinil Diolamine | 23 | $172,003 |
| Dupixent PenDupilumab | 39 | $146,816 |
| Spiriva RespimatTiotropium Bromide | 143 | $93,450 |
| Breo ElliptaFluticasone/Vilanterol | 163 | $85,704 |
| XolairOmalizumab | 18 | $68,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $58,267 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 84 | $54,068 |
| Spiriva HandihalerTiotropium Bromide | 41 | $34,773 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $34,597 |
| Advair HfaFluticasone Propion/Salmeterol | 71 | $29,294 |
| Incruse ElliptaUmeclidinium Bromide | 52 | $23,839 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 146 | $19,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $25 | $810,365286 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $25 | $614,439863 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $15 | $77,558140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Duluth
- Jeray JohnsonDuluth$4K
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Hyun KimMinneapolis$77K
- Jagdeep BijwadiaRochester$54K
- Grady HedstromMinneapolis$50K
- Teng MouaRochester$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.